Health Care, Immuno-Oncology
Early-Stage Immuno-Oncology Company; Pre-IPO Bridge Round
$92.97bn by 2025
Global I/O TAM
Left In the Round
About Cytovia Therapeutics
Cytovia Therapeutics Inc is clinical stage biotechnology company that develops immunotherapies for several unmet medical needs in cancer and infectious diseases. The company has research partnerships with Cellectis, CytoImmune, STC Biologics, the New York Stem Cell Foundation (NYSCF), University of California San Francisco (UCSF), the National Cancer Institute (NCI) and the Hebrew University of Jerusalem.
Cytovia is led and backed by the TF Capital, the largest biotech VC in China, Jack Ma’s Yunfeng, and Biotrack. The Ligo Investor Network has been offered a special opportunity to participate in a bridge round prior to the public offering of a highly anticipated immuno-oncology (I/O) company, the details of which can be discussed with interested parties.